Indiana University School of Medicine led the development of the first blood test approved by the FDA to detect amyloid plaques in the brain, a hallmark of Alzheimer's disease. The test offers a non-invasive, accessible alternative to traditional diagnostic tools, enabling early detection in symptomatic patients aged 55 and older with over 90% accuracy, potentially transforming disease management strategies.